DTI © 2020 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Any commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu ISSN 1177-3928 Drug Target Insights 2020; 14: 1-11 ORIGINAL RESEARCH ARTICLE DOI: 10.33393/dti.2020.1548 Identification of the possible therapeutic targets in the insulin-like growth factor 1 receptor pathway in a cohort of Egyptian hepatocellular carcinoma complicating chronic hepatitis C type 4 Nada M.K. Mabrouk1, Dalal M. Elkaffash2,3, Mona Abdel-Hadi1, Salah-ElDin Abdelmoneim4, Sameh Saad ElDeen3, Gihan Gewaifel6, Khaled A. Elella5, Maher Osman5, Nahed Baddour1 1 Department of Pathology, University of Alexandria, Alexandria - Egypt 2 Alexandria Regional Center for Women’s Health and Development, Alexandria - Egypt 3 Department of Clinical and Chemical Pathology, University of Alexandria, Alexandria - Egypt 4 Department of Clinical Oncology and Nuclear Medicine, University of Alexandria, Alexandria - Egypt 5 Department of General Surgery, University of Alexandria, Alexandria - Egypt 6 Public Health Department, Faculty of Medicine, University of Alexandria, Alexandria - Egypt ABSTRACT Background: Molecular targeted drugs are the first line of treatment of advanced hepatocellular carcinoma (HCC) due to its chemo- and radioresistant nature. HCC has several well-documented etiologic factors that drive hepa- tocarcinogenesis through different molecular pathways. Currently, hepatitis C virus (HCV) is a leading cause of HCC. Therefore, we included a unified cohort of HCV genotype 4-related HCCs to study the expression levels of genes involved in the insulin-like growth factor 1 receptor (IGF1R) pathway, which is known to be involved in all aspects of cancer growth and progression. Aim: Determine the gene expression patterns of IGF1R pathway genes in a cohort of Egyptian HCV-related HCCs. Correlate them with different patient/tumor characteristics. Determine the activity status of involved pathways. Methods: Total ribonucleic acid (RNA) was extracted from 32 formalin-fixed paraffin-embedded tissues of human HCV-related HCCs and 6 healthy liver donors as controls. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) using RT2 Profiler PCR Array for Human Insulin Signaling Pathway was done to determine significantly up- and downregulated genes with identification of most frequently coregulated genes, followed by correlation of gene expression with different patient/tumor characteristics. Finally, canonical pathway analysis was performed using the Ingenuity Pathway Analysis software. Results: Six genes – AEBP1, AKT2, C-FOS, PIK3R1, PRKCI, SHC1 – were significantly overexpressed. Thirteen genes – ADRB3, CEBPA, DUSP14, ERCC1, FRS3, IGF2, INS, IRS1, JUN, MTOR, PIK3R2, PPP1CA, RPS6KA1 – were significantly underexpressed. Several differentially expressed genes were related to different tumor/patient char- acteristics. Nitric oxide and reactive oxygen species production pathway was significantly activated in the present cohort, while the growth hormone signaling pathway was inactive. Conclusions: The gene expression patterns identified in this study may serve as possible therapeutic targets in HCV-related HCCs. The most frequently coregulated genes may serve to guide combined molecular targeted therapies. The IGF1R pathway showed evidence of inactivity in the present cohort of HCV-related HCCs, so target- ing this pathway in therapy may not be effective. Keywords: Gene expression, Hepatitis C virus, Hepatocellular carcinoma, Molecular therapeutic targets Received: January 8, 2020 Accepted: January 20, 2020 Published online: April 8, 2020 Corresponding author: Nada M.K. Mabrouk Department of Pathology University of Alexandria Alexandria, Egypt nada_mabrouk@hotmail.com, nada.mabrouk@alexmed.edu.eg Introduction Hepatocellular carcinoma (HCC) has become the fifth most common cancer in men worldwide and the ninth in women and the third leading cause of cancer-related deaths. Distinct geographical variations in the incidence exist. In Egypt, HCC has the highest age-standardized incidence and mortality rates (ASR) from cancer in males and ranks second in females (1). Most of the burden is in developing countries where 83% of cases (and deaths) occur (2). HCC has several Possible therapeutic targets in IGF1R Pathway in Egyptian HCV related HCC2 © 2020 The Authors. Published by AboutScience well-documented etiologic factors that drive hepatocarcino- genesis through different molecular pathways. Currently, hepatitis C virus (HCV) is a leading cause of HCC. The multi- plicity of etiologies of HCC and the existence of substantial molecular heterogeneity might limit the benefits of targeted approaches to HCC treatment. Therefore, therapeutic vul- nerabilities should be studied in homogeneous groups of HCCs sharing similar drivers of the disease (3). In Egypt, the estimated national prevalence of HCV is 14.7%, which is the highest in the world (4), and HCCs attributable to HCV ac- count for around 50% of cases (5). Studies of the HCV ge- nome confirmed that over 90% of Egyptian HCV isolates be- long to genotype 4 (6). The present study was conducted to characterize the mo- lecular alterations in the insulin-like growth factor 1 receptor (IGF1R) pathway in a unified cohort of Egyptian HCCs compli- cating chronic HCV genotype 4. The IGF1R pathway was cho- sen as its activation plays an important role in almost every aspect of cancer development, including cell proliferation, neoplastic transformation, cancer cell survival, epithelial to mesenchymal transition (EMT), and metastasis (7) and that IGF1R overexpression correlated with aggressive phenotype in cancer, poor clinical outcome, and therapy resistance (8–10). Aim The present work aimed to identify the gene expres- sion of the different subcellular components of the IGF1R pathway in Egyptian HCCs complicating chronic HCV geno- type 4, followed by identification of the most frequently coregulated genes, correlation of gene expression with the different clinical and pathological patient and tumor charac- teristics, and determination of the activity status of involved pathways. Materials Two groups were included in the present study; the study group comprised 32 formalin-fixed, paraffin-embedded (FFPE) blocks from 32 Egyptian HCCs complicating chronic HCV genotype 4 etiology (shown as positive by HCV DNA PCR using Inno-LiPA I and II). Twenty-four out of 32 were segmen- tectomy specimens, while 8 out of 32 were liver explants, and the control group comprised six core biopsies from normal liver donors. Inclusion criteria were HCV genotype 4 etiology and good quantity and quality of extracted ribonucleic acid (RNA) as measured by NanoDrop spectrophotometer (A260:A280 ra- tio 1.9:2.0 indicated pure RNA). Exclusion criteria included positive serology for anti-hepatitis B virus surface antibody and any HCC patient who has received previous neoadjuvant chemotherapy (including transarterial chemoembolization). To accurately define our study population, further iden- tification of other known hepatocarcinogens in the Egyptian environment was performed, including: 1) Hepatitis B core antigen (HBcAg) positivity by immuno- histochemistry (IHC) (denoting occult hepatitis B virus [HBV] infection) was found in 7/29 of our HCC cases as evidenced by cytoplasmic positivity to the antibody. 2) Aflatoxin B1-DNA (AFB1-DNA) adduct positivity by IHC was found to be present in 16/29 of our cases as evi- denced by nuclear positivity to the antibody. Methods The protocol of this study was approved by the Ethics committee of the Faculty of Medicine, University of Alexan- dria. Paraffin blocks of liver biopsies were obtained from the archives of the Pathology Department at the Faculty of Medi- cine, Alexandria University. Clinical data were collected from the patients’ files includ- ing gender, age, comorbidities (diabetes mellitus and obe- sity), alfa-fetoprotein (AFP) levels, liver function tests (alanine aminotransferase [ALT], aspartate transaminase [AST], biliru- bin, and albumin), hemoglobin concentration, and complete blood picture. Gross pathologic examination of HCC tumors specifically addressed tumor size, multifocality, gross capsulation, gross necrosis, satellites, and bile production. Histopathologic study using 5-μm-thick sections assessed pathologic tumor grade (was performed according to the Edmondson and Steiner grading system for HCC), histologic pattern, cell type (including giant cells and clear cells), and vascular invasion. The presence of dysplastic nodules outside HCC and pathological tumor-node-metastasis (pTNM) staging (according to the pTNM staging system of the American Joint Committee on Cancer 8th edition [AJCC]) was also noted. Real-time quantitative reverse transcription PCR Preparation of the paraffin blocks and obtaining tissue sections 1) By trimming off the excess paraffin from the edges of the specimen to facilitate deparaffinization. 2) Then two sections, 5 μm thick each, were cut from each block and placed in a 2 mL nuclease-free microfuge tube. Total RNA was extracted from FFPE tumor sections using the RNeasy® FFPE kit for purification of total RNA from FFPE tissue sections (QIAGEN, Hilden, Germany, cat. no.: 73504) according to the manufacturer’s instructions. Its main prin- ciple is to remove all the paraffin, reverse formalin-induced cross-linking in the nucleic acid, and prevent any further degradation in the RNA that is known to be induced by for- malin and finally to eliminate all genomic DNA. The concen- tration and purity of extracted RNA were determined using a NanoDrop ND-1000 spectrophotometer. Samples were ac- cepted when the A260/A280 ratio (nucleic acid/protein ab- sorbance) was ≥1.9. Reverse transcription of extracted RNA (0.5 µg [500 ng] of RNA was used for all experimental runs) to complementary DNA (cDNA) was done using RT2 First Strand Kit (QIAGEN, Hilden, Germany, cat. no.: 330401) according to the manufacturer’s instructions. RT2 SYBR Green ROX qPCR Mastermix (QIAGEN, Hilden, Germany, cat. no.: 330523) was added to the cDNA. The mixture was aliquoted into the 96 wells of the commercially available RT² Profiler™ PCR Array Human Insulin Signaling Pathway (PAHS-030ZA) (QIAGEN, Mabrouk et al 3 © 2020 The Authors. Published by AboutScience Hilden, Germany, cat. no.: 330231) containing primer assays for 84 genes concerning the human insulin signaling pathway, including genes of the phosphatidylinositol-3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) signal- ing pathways that are the two major downstream signaling pathways for IGF1R signaling (11) and also genes involved in carbohydrate, lipid, and protein metabolism; transcription factors and transcription regulators; genes involved in cell proliferation, growth and differentiation (12); and five house- keeping genes (HKGs). In addition, there were one genomic DNA control, three reverse transcription controls, and three positive PCR controls (the full list of genes can be found in the supplementary file). PCR is then performed using the Applied Biosystems® 7500 Real-Time PCR system (ThermoFisher Sci- entific, Foster City, CA, USA). Finally, relative expression is de- termined using the ΔΔCT method using the RT2 Profiler PCR Array Data Analysis Webportal (at www.SABiosciences.com/ pcrarraydataanalysis.php). Two HKGs with the lowest stan- dard deviations and most stable expression across replicates were selected for data normalization: Beta-2-microglobulin (B2M) (H2) and hypoxanthine phosphoribosyl transferase 1 (HPRT1) (H4). Fold regulation values for each of the 84 genes in HCC cases was determined by the Qiagen online data analysis Webportal (at www.SABiosciences.com/pcrarraydataanalysis. php). Then for each gene the percentages of cases showing upregulation, normal expression, and downregulation were determined. Determination of the significantly up- and down- regulated genes in HCC cases using SPSS statistics software version 20.0 was carried out using nonparametric Mann- Whitney test. The most frequently coregulated genes were identified. Identification of genes significantly correlated with the different patient/tumor characteristics carried out using the Mann-Whitney test. Finally, active and inactive pathways in HCC from the present dataset were identified; an Excel file containing the gene symbols, fold regulation values, and the p values for all 84 tested genes was uploaded to the Ingenuity Pathway Analysis (IPA) software. Results The demographic data of the cases included are pre- sented in Table I. Gross pathological examination of HCC tumors Tumor size ranged from 1.75 to 16.0 cm, with a median of 4.8 cm and a mean of 5.38 ± 3.46 cm standard deviation (SD; Tab. II). Microscopic examination of HCC tumors The most frequently encountered histologic patterns are displayed in Table III. Twenty-six out of 32 cases showed combined histological patterns in the following frequencies (Tab. IV). Frequency of different histopathological features of HCC tumors including Edmonson and Steiner tumor grades is shown in Tables V and VI, respectively. Frequency of pTNM tumor stages is shown in Table VII. TABLE I - Distribution of the studied cases according to demo- graphic data (n = 32) Number % Gender Male 24 75.0 Female 8 25.0 Age (years) ≤60 22 68.8 >60 10 31.3 Min.–Max. 47.0–67.0 Mean ± Standard deviation 56.06 ± 5.49 Median 56.0 Comorbidities 17/25 53.1 Alfa-fetoprotein (≥200 ng/mL) 8/25 25.0 TABLE II - The frequency of the gross characteristics of the tumors included in the present study Gross findings Number % Gross capsulation (n = 32) Absent Present 6 26 18.8 81.3 Gross necrosis (n = 32) Absent Present 21 11 65.6 34.4 Multifocality (n = 32) Absent Present 4 28 12.5 87.5 Satellites (n = 32) Absent Present 6 26 18.8 81.3 Bile production (n = 32) Absent Present 15 17 46.9 53.1 TABLE III - The frequency of the different histologic patterns of the HCC cases included in the present study Histologic pattern of HCC (n = 32) Number % Trabecular Absent 3 9.4 Present 29 90.6 Pseudoglandular Absent 12 37.5 Present 20 62.5 Compact Absent 20 62.5 Present 12 37.5 HCC = hepatocellular carcinoma. Possible therapeutic targets in IGF1R Pathway in Egyptian HCV related HCC4 © 2020 The Authors. Published by AboutScience Significantly up- and downregulated genes A total of 51 deregulated genes were found in the present cohort of HCCs. Fourteen genes were upregulated while 37 genes were downregulated. Statistically significant upregula- tion was observed in HCC patients, in comparison to the con- trol group, in six genes, namely AEBP1, AKT2, FOS, PIK3R1, PRKCI, SHC1, where SHC1 was the most significantly overex- pressed gene (p value: 0.001) (Tab. VIII, Fig. 1). SHC1, AEBP1, AKT2, and PKCI were the most frequently coregulated genes among the significantly upregulated genes. On the other hand, the frequency and magnitude of the downregulation events were greater than that of up- regulation events (Tabs. VIII and IX). Thirteen genes, namely ADRB3, CEBPA, DUSP14, ERCC1, FRS3, IGF2, INS, IRS1, JUN, MTOR, PIK3R2, PPP1CA, and RPS6KA1, were significantly un- derexpressed in HCC patients relative to the control group, where PPP1CA and INS were the two most significantly un- derexpressed genes (p value: 0.002) (Tab. IX, Fig. 1). INS and PPP1CA were the most frequently coregulated genes among the significantly downregulated genes. TABLE IV - The frequency of different combinations of patterns in the tumors included in the present study HCCs with combined histologic pattern Number (%) Trabecular and pseudoglandular Trabecular and compact Trabecular, pseudoglandular, and compact Glandular and compact 15 6 3 2 Total 26 HCC = hepatocellular carcinoma. TABLE V - The frequency of giant cells, clear cells, vascular invasion, and dysplastic nodules in the HCC cases included in the present study Histologic feature Number % Giant cells (n = 32) Absent 17 53.1 Present 15 46.9 Clear cells (n = 32) Absent 17 53.1 Present 15 46.9 Vascular invasion (n = 32) Absent 11 34.4 Present 21 65.6 Dysplastic nodules outside HCC (n= 32) Absent 13 40.6 Present 19 59.4 HCC = hepatocellular carcinoma. TABLE VII - Distribution of the studied cases according to pTNM stage (AJCC 8th Edition) (n = 32) Stage Number % Early stage (1 and 2) 12 37.5 Stage I 5 15.6 Stage II 7 21.9 Advanced stage (3) 20 62.5 Stage III 20 62.5 Stage IV 0 0.0 AJCC = American Joint Committee on Cancer; TNM = tumor-node-metastasis. TABLE VI - Distribution of the studied cases according to Edmond- son and Steiner grading system (n = 32) Grade Number % Low grade (1 + 2) 14 43.8 Grade I 1 3.1 Grade II 13 40.6 High grade (3 + 4) 18 56.3 Grade III 3 9.4 Grade IV 15 46.9 Fig. 1 - Bar chart representing the 6 significantly upregulated and the 13 significantly downregulated genes in the hepatocellular car- cinoma group TABLE VIII - The six significantly upregulated genes’ fold regulation, p values, and percentage of cases showing upregula- tion of these genes Position Gene symbol Fold regulation p Number % A04 AEBP1 6.694 0.045* 29 90.6 A06 AKT2 6.0287 0.013* 26 81.3 C01 FOS 3.9608 0.045* 25 78.1 E11 PIK3R1 4.1363 0.020* 25 78.1 F05 PRKCI 7.7467 0.006* 28 87.5 G04 SHC1 11.8326 0.001* 30 93.8 p = p values for Mann-Whitney test for comparing between the two groups. *Statistically significant at p ≤ 0.05. Mabrouk et al 5 © 2020 The Authors. Published by AboutScience TABLE IX - The 13 significantly downregulated genes’ fold regula- tion, p values, and percentage of cases showing down- regulation of these genes Position Gene symbol Fold regulation p Number % A03 ADRB3 −11.3685 0.010* 23 71.9 B02 CEBPA −5.3981 0.041* 22 68.8 B07 DUSP14 −6.5717 0.016* 23 71.9 B10 ERCC1 −8.7853 0.037* 22 68.8 C03 FRS3 −35.5177 0.006* 27 84.4 D02 IGF2 −8.6788 0.013* 25 78.1 D04 INS −31.7678 0.002* 30 93.8 D07 IRS1 −8.0248 0.037* 22 68.8 D10 JUN −13.0027 0.020* 23 71.9 E04 MTOR −9.0478 0.045* 26 81.3 E12 PIK3R2 −2.8856 0.037* 23 71.9 F03 PPP1CA −46.4755 0.002* 29 90.6 F12 RPS6KA1 −5.653 0.025* 24 75.0 p = p values for Mann-Whitney test for comparing between the two groups. *Statistically significant at p ≤ 0.05. Fig. 2 - Scatter plot representing the normalized expression of each gene on the polymerase chain reaction array between the two groups. Log base 10 of 2–ΔCT value of each gene in the control group is plotted on the x-axis against the corresponding value in the hepatocellular carcinoma (HCC) group, which is plotted on the y-axis to visualize gene expression changes. The central boundary line indicates unchanged gene expression. The upper left section of the scatter plot (above the fold-change boundary lines) contains genes upregulated in the HCC group as compared to the control group. The lower right section of the scatter plot (below the fold-change boundary lines) contains genes down- regulated in the HCC group as compared to the control group. It shows the upregulated genes in red and the downregulated genes in green. Fig. 3 - Heat map is a color-coded representation of fold regulation expression data between HCC and control groups overlaid onto the polymerase chain reaction array plate layout. The black color re- presents the average magnitude of gene expression. The brightest green represents the most downregulated genes, the brightest red represents the most upregulated genes in the HCC cases compared to the normal controls. VEGFA was downregulated (fold regulation of −3.2345) in 71.9% (23/32) of cases in the present study, although this did not reach statistical significance. A scatter plot and a heat map were generated on the on- line data analysis web portal representing the distribution of average gene expression levels (Figs. 1 and 2 respectively). Nonsupervised hierarchical clustering of all cases and controls according to their gene expression profile by the data analysis web portal The included cases were a homogeneous population with no outstanding clustering as evidenced by the dendrograms. This further supports the study design as it included a spe- cific cohort of HCCs: Egyptian ethnicity and HCV genotype 4 etiology. Correlations between the gene expression levels and demographic data in HCC patients Age: There were significant differences in three gene expression levels as regards age; AEBP1, AKT1, and FBP1 genes were significantly overexpressed in HCC patients ≤60 years of age compared to HCC patients >60 years of age (Tab. X). Gender: DOK1 was significantly overexpressed in female patients (p = 0.037). Stage: There were no statistically significant differences detected in the gene expression levels between early pTNM stage (pT1,2) and late stage (pT3,4) HCC tumors. Grade: GSK3A was significantly overexpressed in low- grade tumors as compared to high-grade ones where it was normally expressed (p = 0.002) Possible therapeutic targets in IGF1R Pathway in Egyptian HCV related HCC6 © 2020 The Authors. Published by AboutScience TABLE X - Differentially expressed genes between HCC cases whose age is ≤60 years and those who are >60 years of age as regards human insulin signaling pathway gene expres- sion levels Gene symbol Group 1 Age ≤60 years Group 1 Age >60 years p Fold regulation Fold regulation AEBP1 9.6655 2.9833 0.040* AKT1 2.3142 −1.394 0.024* FBP1 2.1679 −2.1895 0.007* HCC = hepatocellular carcinoma. p = p values for Mann-Whitney test for comparing between the two categories. *Statistically significant at p ≤ 0.05. TABLE XIII - Differentially expressed genes between HCC tumors with clear cells and those without as regards human insulin signaling pathway gene expression levels Clear cells p Absent (n = 17) Present (n = 15) CEBPB −2.34 −12.28 0.010* GPD1 −1.29 −2.64 0.040* HK2 −6.14 −18.17 0.050* IGFBP1 1.22 −3.46 0.041* PIK3R2 −1.41 −6.52 0.021* HCC = hepatocellular carcinoma. p = p values for Mann-Whitney test for comparing between the two categories. *Statistically significant at p ≤ 0.05. Tumor size: Both CEBPB (p = 0.027) and GPD1 (p = 0.002) were significantly downregulated in tumors >5 cm. Dysplastic nodules: No statistically significant difference was detected in the gene expression levels of any genes be- tween cases who had dysplastic nodules outside tumor mass and those who did not have any (none were <0.05). Satellite nodules: AEBP1 and FOS genes were upregu- lated in the absence of satellite nodules more than double their expression level in the cases which showed satellite nodules. MAPK1 gene was overexpressed in the presence of satellite nodules and normally expressed in their absence. PRKCZ and UCP1 genes were downregulated in the absence of satellite nodules and normally expressed in their presence (Tab. XI). Multifocality: AEBP1 and FOS genes were upregulated in the absence of multifocal masses more than double their expression level in the cases which showed multifocal masses. LDLR gene was overexpressed in the absence of multifocal masses and normally expressed in their presence (Tab. XII). Gross capsulation: Both INSL3 (p = 0.043) and IRS1 (p = 0.030) genes were downregulated in the presence of gross capsulation. Gross tumor necrosis: CAP1 (p = 0.041), GRB2 (p = 0.047), PRL (p = 0.024), and TG (p = 0.025) were downregulated in the presence of gross necrosis. PIK3R1 (p = 0.016) was up- regulated in the absence of gross tumor necrosis. Giant cells: Both GSK3A (p = 0.015) and PCK2 (p = 0.030) were upregulated in the absence of giant cells. UCP1 (p = 0.033) was downregulated in tumors that showed giant cells. Clear cells: CEBPB, HK2, GPD1, IGFBP1 and PIK3R2 were downregulated in all the studied cases, more so in tumors that showed clear cells than in tumors which had no clear cells (Tab. XIII). Vascular invasion: NOS2 showed more significant down- regulation in the absence of vascular invasion (p = 0.035). HBcAg: RPS6KA1 was more significantly underexpressed in the presence of HBcAg (p = 0.034). AFB1-DNA adduct positivity: AKT1 and MAPK1 were more significantly upregulated in the presence of aflatoxin as compared to negative cases (p = 0.019, 0.017 respectively). On the other hand, RPS6KA1 was more significantly under- expressed in the presence of AFB1 (p = 0.046). Correlations between the gene expression levels and the different clinical characteristics of the tumors in HCC patients Thrombocytopenia: In patients with a low platelet count, AKT1 was significantly upregulated (p = 0.038) while BCL2L1 TABLE XI - Differentially expressed genes between HCC cases hav- ing satellite nodules around the tumor mass and those without, as regards human insulin signaling pathway gene expression levels Satellite nodules p Absent (n = 6) Present (n = 26) AEBP1 17.44 5.37 0.004* FOS 13.21 3.00 0.007* MAPK1 −1.97 2.05 0.012* PRKCZ −2.63 1.42 0.026* UCP1 −9.60 −1.98 0.014* HCC = hepatocellular carcinoma. p = p values for Mann-Whitney test for comparing between the two categories. *Statistically significant at p ≤ 0.05. TABLE XII - Differentially expressed genes between HCC cases having multifocal tumor masses and those with unifo- cal masses as regards human insulin signaling pathway gene expression levels Multifocality p Absent (n = 4) Present (n = 28) AEBP1 26.30 5.51 0.004* FOS 19.81 3.15 0.003* LDLR 7.12 1.88 0.035* HCC = hepatocellular carcinoma. p = p values for Mann-Whitney test for comparing between the two categories. *Statistically significant at p ≤ 0.05. Mabrouk et al 7 © 2020 The Authors. Published by AboutScience was significantly downregulated (p = 0.045). VEGFA was more significantly underexpressed in the presence of normal plate- let numbers (p = 0.038). Comorbidities: There was no statistically significant dif- ference in the gene expression levels between patients who have comorbidities and those who do not have any. Canonical pathway analysis predicted by IPA database Nitric oxide and reactive oxygen species production path- way was significantly activated in the present cohort, while the growth hormone signaling pathway was significantly in- activated (Fig. 4). Discussion Different etiologic factors result in very diverse HCC molecular profiles between different regions of the world (13,14). Understanding the heterogeneity of HCC is condu- cive to developing personalized therapy and identifying mo- lecular biomarkers. Most published work on molecular profiling of HCC was conducted on heterogeneous groups of tumors including dif- ferent etiologies and ethnic backgrounds (15–19). Once HCC heterogeneity is accepted (20), studies have to be conducted on homogeneous samples to identify characteristic genetic alterations, if personalized management is the target. Fig. 4 - Analysis of canonical pathways involved in hepatitis C virus-related hepatocellular carcinoma pathogenesis with the Ingenuity Pathway Analysis (IPA) database using the present dataset (the 84 tested genes). The IGF pathway was found to be inactive. On the other hand, the nitric oxide and reactive oxygen species production pathway were significantly activated. Description: The white bars mean that half the molecules suggest an activation and half suggest inhibition, so an overall z-score of 0 (Ingenuity Systems). The blue bar indicates that there is evidence that the pathway is inhibited and a negative z-score. The orange bar means that there is a positive z-score indicating that there is evidence for activation of this pathway. The horizontal threshold line indicates the threshold for the over- representation analysis and was set at p = 0.05. Only bars that are more significant than p < 0.05 are shown. The ratio line represents the ratio of the number of molecules in the present dataset that map into the pathway relative to the whole size of the pathway (Ingenuity Systems). The pathway analysis was generated through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ ingenuity-pathway-analysis HCC is known to be chemo- and radioresistant (21); there- fore, identifying therapeutic vulnerabilities for molecular targeted drugs is in dire need. The present study measured levels of messenger RNA (mRNA) expression of 84 insulin signaling-related genes, including genes of the PI3K and the MAPK signaling pathways (11). Also included are genes in- volved in carbohydrate, lipid and protein metabolism, tran- scription factors and transcription regulators, genes involved in cell proliferation, growth, and differentiation (12). Of the 84-cancer pathway-focused genes in this array, upregulation was observed in 14 genes, while 37 genes ap- peared to be downregulated in the tumor samples, for a total of 51 differentially regulated genes. These upregulated genes may be therapeutic targets for future trials, especially those for which molecularly targeted agents are available. Among the significantly upregulated genes was c-FOS, a proto-oncogene which is a major nuclear target for signal transduction pathways, including MAPK pathway, and is in- volved in the regulation of cell growth, differentiation, and transformation (22,23). A novel selective C-FOS/AP-1 inhibi- tor T‐5224 was found to inhibit the invasion and migration of head and neck squamous cell carcinoma cells in vitro and prevented lymph node metastasis in head and neck cancer in an animal model (24). Most of the significantly upregulated genes found in the present work were also found in common with prior HCC Possible therapeutic targets in IGF1R Pathway in Egyptian HCV related HCC8 © 2020 The Authors. Published by AboutScience and clinical trials to be conducted for agents targeting those upregulated genes to test their efficacy and their potential use in HCV-related HCC treatment. The 13 significantly downregulated genes included genes involved in carbohydrate, protein, and lipid metabolism, PI3K signaling target genes, MAPK signaling target genes, insulin re- ceptor-associated proteins, genes involved in cell cycle, cell pro- liferation, growth factors and receptors, insulin gene and insulin receptor-associated proteins, primary insulin signaling target genes, transcription factors, and transcription regulators (12). Two of those were tumor suppressor genes. CEBPA has been described as a tumor suppressor, leading to mitotic arrest through activation of p21 and repression of E2Fs and cyclin-dependent kinases (50). Its expression is downregu- lated in a number of cancers including lung (51), breast can- cers (52), head and neck squamous cell carcinoma (53), and HCC. Its downregulation was associated with advanced HCC stages and poor survival (54,55). Recently, a modified small activating RNA (saRNA) re- tained activation of CEBPA mRNA and downstream targets and inhibited growth of liver cancer cell lines in vitro (56). This novel drug has been encapsulated in a liposomal formu- lation for liver delivery in humans and is currently in a phase I clinical trial for patients with liver cancer and represents the first human study of a saRNA therapeutic (57). FRS3 was significantly downregulated in our patient co- hort. This is the first report of its significant downregulation in HCCs. Similar to our findings, FRS3 expression level has been found to be downregulated in brain and lung cancer cell lines. It constitutively binds to EGFR regardless of EGF stimulation and inhibits EGF-induced cell transformation and prolifera- tion (58). It serves as a tumor suppressor in non-small cell lung cancer (NSCLC) (59). In our work, excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) was sig- nificantly downregulated. It was also found to be downregu- lated in Chinese (47) and Turkish (60) HCC cohorts as well. Loss of ERCC1 expression in hepatocytes may be one of the leading factors for genetic instability, and thus of tumorigen- esis (61). Impaired nucleotide excision repair pathway, in which ERCC1 plays a major role, leads to reduced DNA repair capability and increases DNA adduct levels and genomic in- stability that in turn could lead to a more malignant pheno- type (62). This is not limited to HCCs, but also is a finding in other types of cancer including head and neck squamous cell carcinoma (63). Gene expression patterns can be used to define the suit- able chemotherapeutic agent employed in any given case. ERCC1 overexpression could be associated with resistance to cisplatin-based therapy in HCC, similar to what is observed in NSCLC (64,65). VEGFA was found to be downregulated in the present study in 71.9% of cases. Several retrospective studies sug- gested that tumors with a VEGFA amplification respond better to sorafenib, the only approved first-line treatment of advanced HCC (66), suggesting that further studies of currently used molecularly targeted therapies in Egyptian HCV-related HCC patients are needed, and search for mo- lecular biomarkers of response to therapy with prospective molecular studies; AKT2, C-FOS, PIK3R1, PRKCι, SHC1 were all found to be similarly significantly upregulated (25–30). AEBP1 is an exception; to the best of our knowledge, this is the first report to find this gene to be significantly and consistently (>90% of HCCs) upregulated in HCC. It is a transcriptional re- pressor that has been studied in great detail for its role in regulating adipogenesis (31). It has also been found to be a proinflammatory mediator (32). Finally, it has been shown that AEBP1 induces massive obesity in mice with targeted overexpression of AEBP1 in adipose tissue (33). Although its exact role in tumorigenesis is not clear (34), AEBP1 was found to be upregulated in many different cancers such as cervi- cal cancer (35,36), primary glioblastoma multiforme (37), and human breast cancer cell lines (38). Ladha et al found that silencing AEBP1 expression and loss of its function lead to apoptosis in glioma cell lines, meaning that AEBP1 has an antiapoptotic function and is an important survival factor for tumor cells (34). Two studies found that directly targeting AKT2 by miR- 302b in human HCC cells suppresses cell proliferation, inva- sion, and metastasis in vitro and also inhibited HCC tumor growth in vivo (25,39). A recent preclinical in vitro and in vivo trial using a highly selective allosteric pan-AKT inhibi- tor in combination with sorafenib found that this combina- tion yielded better outcomes and with minimal toxicity than sorafenib alone. The combination significantly reduced tumor growth, proliferation, and angiogenesis and increased apop- tosis (40). The PKCι blocking agent aurothiomalate (ATM) was found to negatively regulate EMT and invasion of HCC in immortal- ized murine hepatocytes and was found to inhibit prolifera- tion and induce apoptosis in HepG2 cells (41). Also, a recent patent has been published on a novel drug targeting PKCι. It has been found to be effective at treating colon cancer cells having high level of expression of at least one aPKC (42). These can potentially be tested in preclinical trials as a method for treating HCCs overexpressing atypical PKCs. Similarly, PKCι was upregulated in HCC in several studies involving different ethnic groups; two Chinese studies (Wang et al (43), Du et al (44)) and an American and Spanish study (Chiang et al (45)). Boyault et al in a French study attempted to classify HCC by unsupervised hierarchical clustering ac- cording to the tumors’ gene expression profiles by microar- ray; all three generated subgroups had upregulated PKCι (the HBV and non-HBV-related HCCs) (46). In line with our findings, PIK3R1 was found to be upregu- lated in HCV-related HCC subgroups (45) and in HCC patients of Chinese ethnicity as well (47). In a recent study by He et al, PIK3R1 transfection by small interfering RNA significantly inhib- ited HCC cell migration and invasion (48). There are several PI3K inhibitors including both pan-PI3K and isoform-specific PI3K in- hibitors that are still in early phase clinical trials (49). The strongest associations between upregulated genes in the present study were between AEBP1, SHC1, AKT2, and PRKCi. Possibly, these associations can serve as a guide to molecularly targeted therapy combinations to cotarget the genes that were most frequently coregulated to maximize the benefits in HCC therapy. These potential therapeutic targets and combinations open several pipelines for future preclinical Mabrouk et al 9 © 2020 The Authors. Published by AboutScience validation of the role of VEGFA expression level to predict response to therapy. One of the points of strength in our study is that we in- cluded HCC samples resulting from a single etiologic agent only (HCV genotype 4-related HCC). Also, the present study unified the controls used in the analysis as we used healthy liver donors as the control group. On the other hand, in the vast majority of studies paired adjacent cirrhotic liver tissues to the HCC tumor masses were used as controls (30,45,67– 69). This complicates the interpretation of results since the gene expression patterns in the nontumor cirrhotic liver samples from different patients can vary significantly, af- fected by the viral infection and degree of fibrosis. Thus, the tumor-specific variation in the expression patterns could not be distinguished from variation due to differences in the cor- responding nontumor liver samples (70). In our cohort, two HKGs – B2M and HPRT1 – were used for data normalization. In a study performed to search for appropriate HKGs to be used for data normalization in HCV- induced HCC specifically. Two of the most commonly used HKGs, which were also included in the standard catalogued 5 HKGs set in the present study’s array, namely glyceralde- hyde-3-phosphate dehydrogenase (GAPDH) and beta-actin (ACTB), were found to be deregulated in HCV-induced HCC (71). Thus, using them for normalization would have strong effects on the extent of differential expression of genes, lead- ing to misinterpretation of results. This was the exact same case in our study for ACTB and GAPDH, which were found to be unstable and had a wide SD across samples. A few weaknesses of this study that we recognize are, firstly, the fact that we were studying patients who already had developed disease at a single point in time. Also, as in most studies on HCC, tumor samples have been collected dur- ing resection. It could be expected that in a more clinically ad- vanced context with tumor progression, increased crosstalk among pathways and chromosomal instability would con- tribute to additional signaling deregulation. These samples do not represent the tumors of patients with advanced stage disease, who do not undergo surgery. However, as HCC diag- nosis at present is not tissue based, obtaining tissue samples from late cases is not feasible at present. Conclusions The significantly up- and downregulated genes identified in the present study can serve as potential therapeutic tar- gets for HCV-related HCCs. In the present study, the insulin pathway genes including IGF1R, IGF2, INS, INSR, and IRS1 were found to be downregu- lated and the IGF pathway was found to be significantly inac- tive, in the present work, which is in concordance with the findings of Zucman-Rossi et al (72). Therefore, drugs targeting the IGF1R pathway may not be suitable for this specific sub- set of HCV-related HCCs. Although NOS2 gene expression was unchanged in our cohort, IPA revealed that nitric oxide pathway and reactive oxygen species production in HCV-related HCCs were signifi- cantly activated. The gene expression pattern of each HCC tumor seems to provide a distinctive molecular portrait of that tumor, as no gene was 100% up- or downregulated in the present co- hort. Personalized medicine mandates the knowledge of the specific genetic profile of each HCC tumor, which is currently not feasible due to costs associated especially in developing countries where most of the HCC burden lies. Therefore, the present study fills a void in this respect – identifying specific morphologic and clinical patient/tumor characteristics, which significantly correlate with underlying molecular alterations. This may be used as a guide for tailoring molecularly targeted therapies. We confirm the findings of a previous study that was per- formed to search for appropriate HKGs to be used for data normalization in HCV-induced HCC specifically. Two of the most commonly used HKGs – ACTB and GAPDH – were found to be unstable and had a wide SD in our study and theirs; therefore these shouldn’t be used for normalization. We sug- gest B2M and HPRT1 to be used instead, as they had more stable levels of expression. Disclosures Financial support: The present study was fully funded by a grant from the “Alexandria Regional Center for Women’s Health and Development,” Alexandria, Egypt (this grant covered all expenses needed for provision of all experimental kits). Conflict of interest: All the authors declare no conflict of interest. References 1. International Agency for Research on Cancer (IARC). Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. France: IARC; 2012. 2. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control stud- ies on the combined effect of hepatitis B and C virus infec- tions in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92(3):607–612. 3. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the ge- nomic era. Nat Rev Clin Oncol. 2015;12(7):408–424. 4. El-zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associ- ates, and Macro International; 2009. 5. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018;142(12):2471-7. 6. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epi- demiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000;182(3):698–707. 7. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti- cancer target: blocking transformation and inducing apoptosis. Curr Cancer Drug Targets. 2002;2(3):191–207. 8. Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Can- cer. 2015;14(1):43. 9. Papa V, Gliozzo B, Clark GM, et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993;53(16):3736–3740. 10. Jones R, Campbell C, Gunther E, et al. Transgenic overexpres- sion of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 2007;26(11):1636–1644. 11. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF sys- tem in cancer growth and metastasis: overview and recent in- sights. Endocr Rev. 2007;28(1):20–47. Possible therapeutic targets in IGF1R Pathway in Egyptian HCV related HCC10 © 2020 The Authors. Published by AboutScience 12. Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Mo- lecular mechanisms of hepatitis c virus–induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22(10):853–861. 13. Patel A, Sun W. Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Opt Oncol. 2014;15(3):380–394. 14. Lu L-C, Hsu C-H, Hsu C, Cheng A-L. Tumor heterogeneity in hepatocellular carcinoma: facing the challenges. Liver Cancer. 2016;5(2):128–138. 15. Luo JH, Ren B, Keryanov S, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblas- tomas. Hepatology. 2006;44(4):1012–1024. 16. Lee JS, Chu IS, Heo J, et al. Classification and prediction of sur- vival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40(3):667–676. 17. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Iden- tification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology. 2001;33(4): 832–840. 18. Tackels-Horne D, Goodman MD, Williams AJ, et al. Identifica- tion of differentially expressed genes in hepatocellular carci- noma and metastatic liver tumors by oligonucleotide expres- sion profiling. Cancer. 2001;92(2):395–405. 19. Patil MA, Chua M-S, Pan K-H, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocel- lular carcinoma. Oncogene. 2005;24(23):3737–3747. 20. Guimei M, Baddour N, ElKaffash D, Abdou L, Taher Y. Gremlin in the pathogenesis of hepatocellular carcinoma complicating chronic hepatitis C: an immunohistochemical and PCR study of human liver biopsies. BMC Res Notes. 2012;5(1):390. 21. Huynh H. Molecularly targeted therapy in hepatocellular carci- noma. Biochem Pharmacol. 2010;80(5):550–560. 22. Saez E, Rutberg SE, Mueller E, et al. C-fos is required for malig- nant progression of skin tumors. Cell. 1995;82(5):721–732. 23. Yuen MF, Wu PC, Lai VCH, Lau JYN, Lai CL. Expression of c-Myc, c-Fos, and c-Jun in hepatocellular carcinoma. Cancer. 2001; 91(1):106–112. 24. Kamide D, Yamashita T, Araki K, et al. Selective activator protein-1 inhibitor t-5224 prevents lymph node metastasis in an oral cancer model. Cancer Sci. 2016;107(5):666–673. 25. Wang L, Yao J, Zhang X, et al. Mirna-302b suppresses human hepatocellular carcinoma by targeting Akt2. Mol Cancer Res. 2014;12(2):190–202. 26. Zhang Y, Guo X, Yang M, Yu L, Li Z, Lin N. Identification of AKT kinases as unfavorable prognostic factors for hepatocellular carcinoma by a combination of expression profile, interac- tion network analysis and clinical validation. Mol BioSyst. 2014;10(2):215–222. 27. Kurokawa Y, Matoba R, Takemasa I, et al. Molecular features of non-B, non-C hepatocellular carcinoma: a PCR-array gene expression profiling study. J Hepatol. 2003;39(6):1004–1012. 28. Huang C-Y, Huang X-P, Zhu J-Y, et al. miR-128-3p suppresses he- patocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients. Oncol Rep. 2015;33(6):2889–2898. 29. Wang JM, Li Q, Du GS, Lu JX, Zou SQ. Significance and expres- sion of atypical protein kinase C-iota in human hepatocellular carcinoma. J Surg Res. 2009;154(1):143–149. 30. Chen X, Cheung ST, So S, et al. Gene expression patterns in hu- man liver cancers. Mol Biol Cell. 2002;13(6):1929–1939. 31. Ro H-S, Roncari D. The C/EBP-binding region and adjacent sites regulate expression of the adipose p2 gene in human preadi- pocytes. Mol Cell Biol. 1991;11(4):2303–2306. 32. Majdalawieh A, Ro HS. Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory media- tor in macrophages. Mediators Inflamm. 2010;2010:823–821. 33. Zhang L, Reidy SP, Nicholson TE, et al. The role of AEBP1 in sex- specific diet-induced obesity. Mol Med. 2005;11(1–12):39. 34. Ladha J, Sinha S, Bhat V, Donakonda S, Rao SM. Identifica- tion of genomic targets of transcription factor AEBP1 and its role in survival of glioma cells. Mol Cancer Res. 2012;10(8): 1039–1051. 35. Han S-J, Cho YL, Nam GH, Kim CK, Seo J-S, Ahn WS. CDNA mi- croarray analysis of gene expression profiles associated with cervical cancer. Cancer Res Treat. 2003;35(5):451–459. 36. Ahn WS, Bae SM, Lee JM, et al. Searching for pathogenic gene functions to cervical cancer. Gynecol Oncol. 2004;93(1):41–48. 37. Reddy SP, Britto R, Vinnakota K, et al. Novel glioblastoma mark- ers with diagnostic and prognostic value identified through tran- scriptome analysis. Clin Cancer Res. 2008;14(10):2978–2987. 38. Grigoriadis A, Mackay A, Reis-Filho JS, et al. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res. 2006;8(5):R56. 39. Wang L, Yao J, Sun H, et al. miR-302b suppresses cell invasion and metastasis by directly targeting AKT2 in human hepatocel- lular carcinoma cells. Tumor Biol. 2016;37(1):847–855. 40. Jilkova ZM, Kuyucu AZ, Kurma K, et al. Combination of AKT in- hibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. Oncotarget. 2018;9(13):11145–11158. 41. Ma C, Yang Y, Wang J, et al. The aPKCι blocking agent atm nega- tively regulates EMT and invasion of hepatocellular carcinoma. Cell Death Dis. 2014;5(3):e1129. 42. Acevedo-Duncan M. Method of treating colorectal cancers us- ing a PKC inhibitor. In: Google Patents; 2018. 43. Wang J-M, Li Q, Du G-S, Lu J-X, Zou S-Q. Significance and ex- pression of atypical protein kinase c-ι in human hepatocellular carcinoma. J Surg Res. 2009;154(1):143–149. 44. Du G-S, Wang J-M, Lu J-X, et al. Expression of P-aPKC-ι, E-cadherin, and β-catenin related to invasion and metastasis in hepatocellular carcinoma. Ann Surg Oncol. 2009;16(6):1578–1586. 45. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Can- cer Res. 2008;68(16):6779–6788. 46. Boyault S, Rickman DS, De Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007;45(1):42–52. 47. De Yun F, Hui Z, Tan Y, Cheng RX. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol. 2001;7(1):33–36. 48. He S, Zhang J, Zhang W, Chen F, Luo R. Foxa1 inhibits hepatocel- lular carcinoma progression by suppressing PIK3R1 expression in male patients. J Exp Clin Cancer Res. 2017;36(1):175. 49. Rodon J, Tabernero J. Improving the armamentarium of PI3K inhibitors with isoform-selective agents: a new light in the darkness. Cancer Discov. 2017;7(7):666–669. 50. Schuster MB, Porse BT. C/EBPalpha: a tumour suppressor in multiple tissues? Biochim Biophys Acta. 2006;1766(1):88–103. 51. Costa DB, Li S, Kocher O, et al. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of e3590. Lung Cancer (Amsterdam, Netherlands). 2007; 56(1):97–103. 52. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res. 2005;11(9):3184–3190. 53. Bennett KL, Hackanson B, Smith LT, et al. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigeneti- cally down-regulated in head and neck squamous cell carci- noma. Cancer Res. 2007;67(10):4657–4664. Mabrouk et al 11 © 2020 The Authors. Published by AboutScience 54. Tseng HH, Hwang YH, Yeh KT, Chang JG, Chen YL, Yu HS. Re- duced expression of C/EBPalpha protein in hepatocellular carcinoma is associated with advanced tumor stage and short- ened patient survival. J Cancer Res Clin Oncol. 2009;135(2): 241–247. 55. Tomizawa M, Watanabe K, Saisho H, Nakagawara A, Tagawa M. Down-regulated expression of the CCAAT/enhancer bind- ing protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker. Anticancer Res. 2003;23(1a):351–354. 56. Voutila J, Reebye V, Roberts TC, et al. Development and mecha- nism of small activating RNA targeting CEBPA, a novel thera- peutic in clinical trials for liver cancer. Mol Ther. 2017;25(12): 2705–2714. 57. Reebye V, Huang KW. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. 2018;37(24):3216-28. 58. Huang L, Watanabe M, Chikamori M, et al. Unique role of SNT-2/FRS2β/FRS3 docking/adaptor protein for negative regu- lation in EGF receptor tyrosine kinase signaling pathways. On- cogene. 2006;25(49):6457. 59. Iejima D, Minegishi Y, Takenaka K, et al. FRS2β, a potential prognostic gene for non-small cell lung cancer, encodes a feed- back inhibitor of EGF receptor family members by ERK binding. Oncogene. 2010;29(21):3087. 60. Turhal N, Bas E, Er O, et al. ERCC1 is not expressed in hepato- cellular cancer: a Turkish oncology group, gastrointestinal on- cology subgroup study. J Buon. 2010;15(4):794–796. 61. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression lev- els of nucleotide excision repair genes in lung cancer: a case- control analysis. Carcinogenesis. 2000;21(8):1527–1530. 62. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 ex- pression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005;127(3):978–983. 63. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer. 2002;94(2):393–397. 64. Ueda S, Shirabe K, Morita K, et al. Evaluation of ERCC1 expres- sion for cisplatin sensitivity in human hepatocellular carci- noma. Ann Surg Oncol. 2011;18(4):1204–1211. 65. Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Lan- gouët S: Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol. 2005;43(2):288–293. 66. Lopez PM, Patel P, Uva P, Villanueva A, Llovet JM. Current man- agement of liver cancer. Eur J Cancer Suppl. 2007;5(5):444–446. 67. Xu XR, Huang J, Xu ZG, Qian BZ, et al. Insight into hepatocel- lular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA. 2001;98(26):15089–15094. 68. Boyault S, Rickman DS, de Reynies A, et al. Transcriptome clas- sification of HCC is related to gene alterations and to new ther- apeutic targets. Hepatology. 2007;45(1):42–52. 69. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepa- tology. 2003;37(1):198–207. 70. Makowska Z, Boldanova T, Adametz D, et al. Gene expression analysis of biopsy samples reveals critical limitations of tran- scriptome-based molecular classifications of hepatocellular carcinoma. J Pathol Clin Res. 2016;2(2):80–92. 71. Waxman S, Wurmbach E. De-regulation of common house- keeping genes in hepatocellular carcinoma. BMC Genomics. 2007;8:243. 72. Zucman-Rossi J, Villanueva A, Nault J-C, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gas- troenterology. 2015;149(5):1226–1239. e1224.